Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyra Therapeutics, Inc. - Common Stock (NQ:LYRA)

4.930 -0.080 (-1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Lyra Therapeutics: Q2 Earnings Insights
  Lyra Therapeutics (NASDAQ:LYRA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor
Via Benzinga
Recap: Lyra Therapeutics Q1 Earnings
Lyra Therapeutics (NASDAQ:LYRA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
Lyra Therapeutics (NASDAQ: LYRA) advanced into its Part 2 of the Phase 2 BEACON clinical trial of LYR-220 in adults with chronic rhinosinusitis (CRS) who have had a prior sinus surgery. 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
Lyra Therapeutics Stock Surges On Equity Raise Of $100M
Via Benzinga
Lyra Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
7 Stocks to Watch for Major Insider Trading Clues
These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. 
Via InvestorPlace
90 Biggest Movers From Yesterday
Gainers 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Another day of trading is waiting for investors and we're kicking it off with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
54 Biggest Movers From Yesterday
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals'... 
Via Benzinga
Executives Buy More Than $32M Of 4 Stocks
Although U.S. stock futures traded lower this morning on Monday, there were a few notable insider trades. 
Via Benzinga
51 Biggest Movers From Thursday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of... 
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2%
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ... 
Via Benzinga
Mid-Day Market Update: Dow Jumps Over 200 Points; Sunshine Biopharma Shares Slide
U.S. stocks traded mixed midway through trading, with the Dow Jones surging more than 200 points on Friday. 
Via Benzinga
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday
We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! 
Via InvestorPlace
Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers iRadimed (NASDAQ:IRMD) stock rose 15.0% to $45.19 during Friday's regular session. Trading volume for iRadimed's stock is 94.1K as of 12:30 EST. This is... 
Via Benzinga
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients
Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients.... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.